EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and Safety of Phosphate-Lowering Agents for Adult Patients with CKD Requiring Dialysis

Masatoshi Nishimoto, Takeshi Hasegawa iD, Miho Murashima iD, Hisashi Noma iD, Hiroki Nishiwaki iD, Shunsuke Yamada, Aya Mizukami iD, Hirotaka Saito, Hiroshi Kimura, Masatomo Taniguchi, Takayuki Hamano iD, Masafumi Fukagawa

Clinical Journal of the American Society of Nephrology · 2025-05 · 20 (5) · 676-696

DOI: 10.2215/cjn.0000000665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 14.03.2025. Verfasst von Masatoshi Nishimoto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Nara Medical University, Nara, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science London.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Sevelamer was associated with lower all-cause mortality compared with calcium-based agents. Sucroferric oxyhydroxide and tenapanor were estimated to rank high in lowering all-cause mortality compared with other phosphate-lowering agents. Sucroferric oxyhydroxide and lanthanum were associated with slower progression of coronary artery calcium score compared with calcium-based agents.

Background

It is necessary to update the evidence of each phosphate-lowering agent on dialysis patients.

Methods

From the CENTRAL, MEDLINE, Embase, and ClinicalTrial.gov databases, randomized controlled trials using oral phosphate-lowering agents on adult patients requiring maintenance dialysis were extracted. The treatment period was required for 8 or more weeks, and the risk of bias was assessed according to the Cochrane Collaboration method. The outcomes were all-cause mortality, cardiovascular mortality, gastrointestinal events, fracture, coronary artery calcium score (CACS), serum calcium, phosphate, intact parathyroid hormone, and bicarbonate levels. A network meta-analyses using multivariate random-effects models were performed for assessing the comparative effectiveness. The ranking of the phosphate-lowering agents was assessed using a surface under the cumulative ranking curve.

Results

A total of 70 randomized controlled trials involving 15,551 participants were included. Eleven phosphate-lowering agents including calcium-based agents, sevelamer, bixalomer, lanthanum, sucroferric oxyhydroxide, ferric citrate, tenapanor, magnesium, nicotinamide, aluminum, and sucralfate were assessed. Sevelamer was significantly associated with lower all-cause mortality compared with calcium-based agents (risk ratio [95% confidence interval]: 0.59 [0.37 to 0.94]), and sucroferric oxyhydroxide and tenapanor were estimated to rank high in lowering all-cause mortality on the basis of the surface under the cumulative ranking curve. The risk of gastrointestinal events was the highest with nicotinamide, followed by sucroferric oxyhydroxide. Compared with calcium-based agents, CACS was significantly lower among those on lanthanum and sucroferric oxyhydroxide (standardized mean difference [95% confidence interval]: −0.26 [−0.52 to −0.01] and −0.50 [−0.95 to−0.06], respectively). Serum calcium levels were higher, and serum intact parathyroid hormone levels were lower in patients treated with calcium-based agents. Except for sevelamer, serum bicarbonate levels for all other agents were higher compared with placebo.

Conclusions

Compared with calcium-based agents, sevelamer was associated with lower all-cause mortality, and sucroferric oxyhydroxide and lanthanum were associated with slower progression of CACS. Potential benefits and harms should be considered when selecting phosphate-lowering agents (International prospective register of systematic reviews: CRD42022328388).

Schlagwörter

Stichwörter der Autor:innen

ESKDphosphate binders

Autor:innen und Institutionen

  • Department of Nephrology, Nara Medical University, Nara, Japan.
  • Institute of Clinical Epidemiology (iCE), Showa Medical University, Tokyo, Japan.
  • Department of Hygiene, Public Health and Preventive Medicine, Showa University Graduate School of Medicine, Tokyo, Japan.
  • Department of Nephrology, Showa University Graduate School of Medicine, Tokyo, Japan.
  • Showa University Research Administration Center, Showa Medical University, Japan.
  • Division of Nephrology, Department of Internal Medicine, Kindai University Faculty of Medicine, Osaka, Japan.

ORCID-Profile: Takeshi Hasegawa, Miho Murashima, Hisashi Noma, Hiroki Nishiwaki, Aya Mizukami, Takayuki Hamano

Förderung

  • Japan Society for the Promotion of Science London

Zitieren

APA

Nishimoto, M., Hasegawa, T., Murashima, M., Noma, H., Nishiwaki, H., Yamada, S., Mizukami, A., Saito, H., Kimura, H., Taniguchi, M., Hamano, T., & Fukagawa, M. (2025). Efficacy and Safety of Phosphate-Lowering Agents for Adult Patients with CKD Requiring Dialysis. Clinical Journal of the American Society of Nephrology, 20(5), 676-696. https://doi.org/10.2215/cjn.0000000665

Vancouver

Nishimoto M, Hasegawa T, Murashima M, Noma H, Nishiwaki H, Yamada S, et al. Efficacy and Safety of Phosphate-Lowering Agents for Adult Patients with CKD Requiring Dialysis. Clinical Journal of the American Society of Nephrology. 2025;20(5):676-696. doi:10.2215/cjn.0000000665

BibTeX
@article{Nishimoto2025,
  author = {Nishimoto, Masatoshi and Hasegawa, Takeshi and Murashima, Miho and Noma, Hisashi and Nishiwaki, Hiroki and Yamada, Shunsuke and Mizukami, Aya and Saito, Hirotaka and Kimura, Hiroshi and Taniguchi, Masatomo and Hamano, Takayuki and Fukagawa, Masafumi},
  title = {Efficacy and Safety of Phosphate-Lowering Agents for Adult Patients with CKD Requiring Dialysis},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2025},
  volume = {20},
  number = {5},
  pages = {676--696},
  doi = {10.2215/cjn.0000000665}
}
Kostenlos starten →